Brokerages Set BioAtla, Inc. (NASDAQ:BCAB) Target Price at $4.00

Shares of BioAtla, Inc. (NASDAQ:BCAB) have earned a consensus recommendation of “Hold” from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $4.00.

BCAB has been the subject of a number of research reports. Rodman & Renshaw initiated coverage on BioAtla in a report on Tuesday, January 13th. They set a “buy” rating and a $4.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAtla in a research report on Friday, January 9th.

BioAtla Stock Performance

Shares of NASDAQ BCAB opened at $0.18 on Friday. The company has a market cap of $11.71 million, a PE ratio of -0.16 and a beta of 1.10. The business has a 50-day simple moving average of $0.50 and a two-hundred day simple moving average of $0.59. BioAtla has a fifty-two week low of $0.14 and a fifty-two week high of $1.43.

BioAtla (NASDAQ:BCAB) last released its earnings results on Thursday, November 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.04. On average, sell-side analysts predict that BioAtla will post -1.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioAtla

Several institutional investors and hedge funds have recently modified their holdings of the stock. Sheets Smith Investment Management acquired a new stake in BioAtla during the third quarter worth about $46,000. Woodline Partners LP acquired a new stake in shares of BioAtla during the 1st quarter worth approximately $26,000. Vanguard Group Inc. increased its holdings in shares of BioAtla by 9.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock valued at $1,339,000 after purchasing an additional 162,647 shares in the last quarter. Susquehanna International Group LLP lifted its stake in shares of BioAtla by 237.6% in the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after purchasing an additional 177,760 shares during the period. Finally, Millennium Management LLC purchased a new stake in BioAtla during the third quarter worth $235,000. Institutional investors and hedge funds own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.